MediLink Therapeutics
Suzhou, China· Est.
MediLink Therapeutics develops next-generation antibody-drug conjugates (ADCs) and other targeted oncology therapies using its proprietary linker and conjugation platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
About
MediLink Therapeutics develops next-generation antibody-drug conjugates (ADCs) and other targeted oncology therapies using its proprietary linker and conjugation platform.
OncologyAntibodiesDrug Delivery